一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy，当前状态为尚未开始招募。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Cancer Hospital & Institute · 北京
公开的入选条件
- 1. Signed written informed consent before any trial-related procedure.
- 2. Age ≥18 and ≤79 years, male or female.
- 3. Histopathologically confirmed colorectal adenocarcinoma; liver metastasis confirmed by pathology or imaging.
- 4. No prior first-line systemic therapy (targeted, immunotherapy, systemic chemotherapy) specifically for liver metastases.
- 5. At least 1 measurable lesion per RECIST 1.1.
- 6. Multidisciplinary-team-confirmed initially unresectable colorectal liver metastases (cannot achieve R0/R1 resection; or predicted future remnant liver volume \< 30 %; or insufficient hepatic inflow/outflow). Patients with extra-hepatic metastases (excluding
- 7. Microsatellite-stable (MSS) / mismatch-repair-proficient (pMMR) confirmed by IHC or PCR.
- 8. ECOG Performance Status 0-1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07815288；登记信息更新于 2026-09-11。